Overview
Registration
Agenda
View Archive

Accreditation/
Credit Designation

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme Corp.

Oncology Town Hall®: Primary Investigators Present Key Abstracts in Gynecologic Cancer Management

Oncology Town Hall®: Primary Investigators Present Key Abstracts in Gynecologic Cancer Management


August 11, 2020

Live Webcast! 8:00 PM - 9:30 PM EDT

Overview

Gynecologic malignancies are an important cause of morbidity and mortality for women in the United States. Patients with ovarian cancer are frequently diagnosed at an advanced stage for which the 5-year survival rate is dismal. Early-stage management of cervical and endometrial cancer is generally managed effectively by hysterectomy, but for patients with locally advanced or metastatic disease, the choices are less certain. The poly(ADP-ribose) polymerase (PARP) inhibitors are a major recent advancement and have changed the treatment landscape for ovarian cancer, and are being investigated in other tumor types as well. Targeted therapy, immunotherapy, and combined therapeutic strategies are also under active investigation in gynecological malignancies.

This activity will update oncology health care professionals with the most recent data from key abstracts presented at major cancer conferences so that they can assess and apply these findings to their clinical practice and ultimately improve care for patients with gynecologic malignancies.

Benefits of Attending

  • Hear the experts present their findings from recent oncology conferences
  • Understand the clinical impact of recent data
  • Submit your questions to the expert faculty panel
  • Determine if emerging treatment strategies are right for your patients

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharpe and Dohme Corp.

Target Audience

This educational activity is directed toward oncologists and fellows who treat patients with gynecologic cancers. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of gynecologic cancers will also be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Evaluate recently reported clinical trial data applicable to the care of patients with gynecologic cancers.
  • Integrate emerging data into a plan of care to optimize outcomes for patients with gynecologic cancer.
  • Assess the design and patient eligibility for ongoing gynecologic cancer clinical trials and treatment regimens under investigation.

Hot Topics

  • PARP inhibitors in ovarian cancer: SOLO1 versus PAOLA1
  • PARP inhibitors in ovarian cancer: Starting dose from PRIMA
  • PARP inhibitors in ovarian cancer: Overall survival from SOLO2
  • Anti-PD1 therapy in DNA mismatch repair deficiency (dMMR) endometrial cancer
  • Combination TKI and checkpoint inhibitors in advanced/recurrent endometrial cancer
  • Targeting TGF-beta and PD-L1 in cervical cancer



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By